Bank of New York Mellon
ENVB icon

Bank of New York Mellon’s Enveric Biosciences ENVB Stock Holding History

Bank of New York Mellon’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2
Closed -$65K – 4414
2021
Q1 		$65K Buy
+2
New +$69.9K ﹤0.01% 4221
2019
Q1 		– Hold
0
– -$42K – 4220
2018
Q4 		– Hold
0
– – – 4080

Other funds holding ENVB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Bank of New York Mellon's ENVB Position: Q2 2021 in Review

Bank of New York Mellon sold out of Enveric Biosciences (ENVB) in Q2 2021, closing a stake of 2 shares — an estimated $65K sold.

Bank of New York Mellon first reported a position in ENVB in Q1 2021 and held it in 1 quarter. The position peaked at $65K in Q1 2021. 14 funds tracked by Wall St. Rank hold ENVB as of Q2 2021.

  • Bank of New York Mellon reported no remaining Enveric Biosciences position as of Q2 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 2 Enveric Biosciences shares in Q2 2021, an estimated $65K.
  • Bank of New York Mellon first reported a position in Enveric Biosciences in Q1 2021 and held it in 1 quarter.
  • Bank of New York Mellon's Enveric Biosciences position peaked at $65K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.